Effect of physical activity on menopausal symptoms

Completed

• Conditions: Menopausal symptoms; Urological and Genital Diseases; Menopausal and other perimenopausal disorders

• Registration Number: ISRCTN54690027
• Lead Sponsor: The Urho Kaleva Kekkonen (UKK) Institute for Health Promotion Research (Finland)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-12-17
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 200

Inclusion Criteria

1. Symptomatic (severe or very severe or moderate daily hot flushes) women
2. Aged 40 - 60 years
3. No current use of oestrogen hormone treatment (HT, without or with progesterone) or any other treatment or withdrawal (wash-out period 3 months)
4. Sedentary (physical exercise less than twice weekly)
5. Six to 36 months from last menstruation (peri-menopausal)
6. Follicle stimulating hormone (FSH) elevated (at least 30 IU/l)

Exclusion Criteria

1. Physically active women (greater than two times/week, at least 30 minutes)
2. Body mass index (BMI) greater than 35 kg/m^2
3. Coronary heart disease, orthopaedic or other diseases preventing from exercising

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Vasomotor symptoms as measured with validated scale (Women's Health Questionnaire [WHQ]). WHQ enables assessment of depression, anxiety, sleep problems, somatic symptoms with optional subscales for menstrual problems and sexual difficulties.<br><br>Timepoint of the measurements is 0 and 6 months; baseline and end of the trial in both primary and secondary outcomes.

Secondary Outcome Measures

Name	Time	Method
1. Other menopausal symptoms, such as urogenital and cognitive symptoms<br>2. Physical activity and health-related physical fitness (estimated maximal oxygen consumption, muscle strength)<br>3. Components of metabolic syndrome (weight, waist circumference, and fasting plasma high density lipoprotein [HDL] cholesterol, triglycerides, glucose and insulin)<br>4. Workability<br><br>Timepoint of the measurements is 0 and 6 months; baseline and end of the trial in both primary and secondary outcomes.